Hybio Pharmaceutical Co., Ltd. (300199)
Market Open
10 Aug, 06:57
XSHE XSHE Primary ¥
25. 24
+0.86
+3.5275%
¥
17.78B Market Cap
- P/E Ratio
0.8% Div Yield
64.85M Volume
- Eps
¥ 24.38
Previous Close Want to track 300199 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
300199 trading today higher at ¥25.24, an increase of 3.5275% from yesterday's close, completing a monthly increase of 13.1839% or ¥2.94. Over the past 12 months, 300199 stock gained 40.0666%.
300199 is not paying dividends to its shareholders.
The last earnings report, released on Oct 29, 2025, missed the consensus estimates by -0.0839%. On average, the company has surpassed earnings expectations by 0.0269%, based on the last three reports.
Hybio Pharmaceutical Co., Ltd. has completed 3 stock splits, with the recent split occurring on Apr 14, 2015.
The company's stock is traded on one exchange.
300199 Chart
People also search for
Hybio Pharmaceutical Co., Ltd. (300199) FAQ
What is the stock price today?
The current price is ¥25.24.
On which exchange is it traded?
Hybio Pharmaceutical Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 300199.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.8%.
What is its market cap?
As of today, the market cap is 17.78B.
Has Hybio Pharmaceutical Co., Ltd. ever had a stock split?
Hybio Pharmaceutical Co., Ltd. had 3 splits and the recent split was on Apr 14, 2015.
Hybio Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Shaogui Zeng CEO | XSHE Exchange | CNE1000011T7 ISIN |
| CN Country | 1,035 Employees | 19 Apr 2018 Last Dividend | 26 Apr 2013 Last Split | 7 Apr 2011 IPO Date |
Overview
Hybio Pharmaceutical Co., Ltd. is a specialized entity in the pharmaceutical sector, centering its efforts on the development, manufacturing, and international commercialization of therapeutic peptides and peptide-based drugs. With a foundation laid in 1998 and headquartered in Wuhan, China, the company stands as a significant player in the field, extending its market reach both domestically and globally. Hybio Pharmaceutical is known for its rigorous adherence to quality and innovation, ensuring that their production processes and products meet the demanding standards of the EU and FDA alike.
Products and Services
- Liraglutide, Semaglutide, and Exenatide for Diabetes: These products signify Hybio Pharmaceutical's commitment to addressing diabetes, offering advanced therapeutic peptides that aim to regulate blood sugar levels effectively.
- Terlipressin, Desmopressin, and Linaclotide for Digestive Tract and Metabolic System: Targeted treatments for various disorders of the digestive tract and metabolic system, ensuring better health outcomes for patients suffering from these conditions.
- Ganirelix, Cetrorelix, and Atosiban for Obstetrics and Gynecology: These offerings cement the company’s stance in providing solutions within the reproductive health and gynecology arena, aiming to assist in the management and treatment of conditions afflicting female reproductive health.
- Customized Peptides: Hybio offers tailor-made peptide solutions, catering to the unique needs of their clients and ensuring that specific research and therapeutic goals are met with precision.
- Working Standards for the Peptide APIs and Related Impurities: The company provides high-quality working standards to ensure the efficacy and safety of peptide APIs, alongside meticulous analysis of possible impurities.
- Peptide CRO and CDMO Services: Comprehensive contract research (CRO) and manufacturing services (CDMO) are at the core of Hybio's offerings, encompassing peptide API synthesis, purification process development, finish dosage form development, reference standard preparation, and more. These services are tailored to fit the stringent GMP standards as recognized by both EU and FDA regulations, with extensive support in regulatory and dossier preparation aspects.
Contact Information
Address: No. 9, Linkong West Street, Wuhan, China
Phone: 86 75 5265 88037
Website: https://www.hybio.com.cn
